News Image

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Provided By GlobeNewswire

Last update: Dec 8, 2024

NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F

Read more at globenewswire.com

BEAM THERAPEUTICS INC

NASDAQ:BEAM (2/21/2025, 8:03:04 PM)

After market: 31 +0.57 (+1.87%)

30.43

-2.71 (-8.18%)



Find more stocks in the Stock Screener

Follow ChartMill for more